ocular diseases

Biotech

Editas shelves lead asset after disappointing phase 1/2 data

Editas is shelving its lead asset after phase 1/2 data found that it was most effective in a very small population with little market upside.
Max Bayer Nov 17, 2022 10:22am

Intellia expands ocular pipeline with 10% stake in SparingVision

Oct 13, 2021 7:00am

Visus, with one drug chasing AbbVie, inks deals to grow pipeline

Aug 19, 2021 8:35am

Immunocore gets FDA breakthrough nod for eye melanoma drug

Feb 19, 2021 8:45am

Psychedelics relieve asthma in rats with no mental effects

Aug 13, 2020 8:00am

Aldeyra halts trials, focuses on ocular assets to stretch runway

Mar 12, 2020 10:20am